Merck's Dividend Sustainability in Question Amid KEYTRUDA QLEX Approval

Merck & Co Inc (NYSE: MRK) has received regulatory approval in Japan for KEYTRUDA QLEX, a new subcutaneous formulation of its blockbuster immuno-oncology drug Keytruda.

This innovative delivery method promises faster administration times and maintains comparable efficacy to traditional intravenous Keytruda, potentially enhancing patient convenience and adherence.

However, concerns have been raised about the sustainability of Merck's dividend due to a payout ratio exceeding 100%, which is notably high at 1.05, indicating that the company is distributing more in dividends than it earns in net income.

The GF Value metric estimates Merck's intrinsic value at $120.75 per share, compared to the current price of $146.87, implying the stock is approximately 21.6% overvalued.